Feb 5, 2018 8:30 am EST EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery
Dec 19, 2017 8:30 am EST EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye
Dec 18, 2017 8:30 am EST EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment
Nov 14, 2017 8:00 am EST EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Nov 8, 2017 8:30 am EST EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery
Nov 1, 2017 8:30 am EDT EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy
Sep 11, 2017 6:30 am EDT EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships